Christian Grøndahl received his Doctor of Medical Science, PhD and Doctor of Veterinary Medicine degrees from University of Copenhagen and his MBA from IMD, University of Lausanne, Switzerland. Christian worked as a veterinary physician/surgeon and assistant professor before moving to pharma and biotech where he has spent the last 20+ years in R&D, Corporate and Executive roles.
Before co-founding SNIPR Biome, he served as the CEO of Kymab Ltd. in Cambridge, UK, and was partner in the investment arm of The Wellcome Trust, London, Syncona LLP. Christian has been part of starting several companies. In addition to SNIPR Biome, this includes Freeline Therapeutics, Gyroscope Therapeutics, Quadrucept Bio Ltd., and Folium Food Science. Christian served as Executive Vice President, CSO and Head of R&D in Zealand Pharma and was part of taking the company through an IPO in 2010. Christian served in VP and Corporate VP roles with Novo Nordisk, heading up Cancer and Inflammation, Women’s Health, eClinical Development and Corporate Development and Strategy. Christian is the co-inventor on 20+ patents and patent applications licensed to public and private companies.
Presently, Christian serves as the Co-founder, CEO and Director, SNIPR Biome APS (Copenhagen, Denmark), Co-founder and Director, QUADRUCEPT BIO Ltd. (Cambridge, UK), Co-founder and Chairman of the Board, FOLIUM SCIENCES Ltd. (Cambridge, UK), Non-exec Director BioMe Oxford Ltd., (Oxford, UK).